Minivelle and Lunesta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Minivelle (estradiol) and Lunesta (eszopiclone). Common drug interactions include application site burn among females.

The phase IV clinical study analyzes what interactions people have when they take Minivelle and Lunesta. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Minivelle?

Minivelle has active ingredients of estradiol. eHealthMe is studying from 3,480 Minivelle users. Check the latest studies of Minivelle.

What is Lunesta?

Lunesta has active ingredients of eszopiclone. It is often used in insomnia. eHealthMe is studying from 26,936 Lunesta users. Check the latest studies of Lunesta.

On Jul, 06, 2026

12 people who take Minivelle and Lunesta together, and have interactions are studied.

Minivelle and Lunesta drug interactions.

What are the common drug interactions of Minivelle and Lunesta, by gender? *:

female:

Application site burn
Application site pruritus (application site severe itching of the skin)
Application site scar
Application site urticaria
Asthma
Complex regional pain syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet))
Death
Drug ineffective
Dry eye (lack of adequate tears)
Dry mouth

male:

n/a

What are the common drug interactions of Minivelle and Lunesta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Pruritus (severe itching of the skin)
Dry mouth
Gingival hyperplasia (overgrowth of gums)
Hypoaesthesia (reduced sense of touch or sensation)
Leukoplakia (white and gray patches inside the mouth)
Ligament disorder (disease of ligament)
Lip dry
Oral papilloma (viral infection of mouth)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Rotator cuff syndrome (a spectrum of conditions affecting the rotator cuff tendons of the shoulder)

50-59:

Application site burn
Application site discolouration
Application site erythema (redness of the skin at application site)
Application site irritation
Application site papules (solid elevation of skin with no visible fluid at application site)
Application site pruritus (application site severe itching of the skin)
Application site scar
Application site urticaria
Drug ineffective

60+:

Application site burn
Application site pruritus (application site severe itching of the skin)
Ocular hyperaemia (an abnormally large amount of blood in eye)
Photophobia (extreme sensitivity to light)
Somnolence (a state of near-sleep, a strong desire for sleep)
Upper respiratory tract infection
Vision blurred
Chronic kidney disease
Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)

What are the existing conditions these people have? *

Sleep Disorder: 2 people, 16.67%
Bipolar Disorder (mood disorder): 2 people, 16.67%
Depression: 2 people, 16.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 16.67%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 16.67%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 8.33%
Indigestion: 1 person, 8.33%
Birth Control: 1 person, 8.33%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 8.33%
Cough: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Minivelle and Lunesta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously